NCT02523014 2026-04-07
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Alliance for Clinical Trials in Oncology
Phase 2 Recruiting
Clinical Trials
10 trialsNCT05651828 2026-04-01
Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Recruiting
NCT06616623 2026-02-27
Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
Ohio State University Comprehensive Cancer Center
Phase 1 Recruiting
NCT05538091 2025-11-26
Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
University of Pittsburgh
Phase 2 Recruiting
NCT05561634 2025-09-30
RADIOSONIC
University Hospital, Lille
Phase 2 Recruiting
NCT04341181 2025-07-25
ProTarget
Rigshospitalet, Denmark
Phase 2 Recruiting
NCT05463757 2025-04-04
Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study
Maastricht University Medical Center
Recruiting
NCT05159245 2024-07-15
FINPROVE
Helsinki University Central Hospital
Phase 2 Recruiting
NCT04817956 2024-02-29
IMPRESS-N
Oslo University Hospital
Phase 2 Recruiting
NCT02925234 2024-01-24
DRUP
The Netherlands Cancer Institute
Phase 2 Recruiting